PMC9984937_01
Keratinizing moderately differentiated squamous cell carcinoma invading subcutaneous adipose tissue (a, c), parotid gland (b), with a metastasis to an intraparotid lymph node (d). Hematoxylin and eosin-stained sections photographed at x20 magnification (a, d), x40 (b), and x100 (c).
cro-2023-0016-0001-528414_f1.jpg
PMC9984937_01_cro-2023-0016-0001-528414_f1.jpg
F1
Figure 1 shows the carcinoma involving subcutis, parotid gland, and an intraparotid lymph node.
Radiologic imaging of patient case. a Baseline scan from August 2020 prior to treatment. b Disease response during cemiplimab treatment. c Radiographical imaging supporting the duration of response to cemiplimab even after being off treatment for 13 months.
cro-2023-0016-0001-528414_f2.jpg
PMC9984937_01_cro-2023-0016-0001-528414_f2.jpg
F2
At this time, his case was reviewed at multidisciplinary rounds, and it was decided to start cemiplimab in August of 2020 (see Fig. 2 for radiographical representation). Routine scans, up to 13 months from the last cemiplimab treatment, revealed stability of disease (see Fig. 2). However, after 16 months from his last dose of cemiplimab, a new nodule deep and inferior to the right sternocleidomastoid muscle was seen on CT scan, measuring 8 x 14 mm (see Fig. 2).
Timeline of important events.
cro-2023-0016-0001-528414_f3.jpg
PMC9984937_01_cro-2023-0016-0001-528414_f3.jpg
F3
A full representation of the timeline for the disease occurrence and treatments is shown in Figure 3.